Skip to Main Content

Paper Details

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Int J Infect Dis
18
2023
Author NameAffiliation
Neil R AggarwalUniversity of Colorado School of Medicine
Tellen D BennettUniversity of Colorado School of Medicine, USA Colorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus
Seth RussellUniversity of Colorado School of Medicine
Adit A GindeColorado Clinical and Translational Sciences Institute, University of Colorado Anschutz Medical Campus, University of Colorado School of Medicine
  • 1 - 4

Datasets